← All themes

Genomics & Gene Editing

Genomics reads the genetic code and gene editing rewrites it, which can turn an inherited disease from a lifelong condition into a single treatment. Sequencing cost has fallen far enough to make study at population scale routine.

199 stocks

Gene Therapy

#	Name	Funds holding	Growth	Growth %	Fund value
51	51 Imunon IMNN $5.95M	26	0	0%	$9.95M
52	52 CareDx CDNA $3.45B	24	-2	-8%	$29.8M
53	HTGM 53 DELISTED HTG Molecular Diagnostics, Inc. Common Stock HTGM	21	+21	–	$41.5M
54	54 DELISTED BRAINSTORM CELL THERAPUTC BCLI	20	-1	-5%	$6.48M
55	55 Ocugen OCGN $276M	19	+5	+36%	$34.8M
56	56 Rocket Pharmaceuticals RCKT $259M	19	+4	+27%	$51M
57	57 Capricor Therapeutics CAPR $423M	14	+7	+100%	$2.9M
58	CYAD 58 DELISTED Celyad Oncology SA American Depositary Shares CYAD	13	+13	–	$39.4M
59	ONCS 59 DELISTED OncoSec Medical Incorporated ONCS	12	+12	–	$5.67M
60	60 DELISTED BioLife Solutions BLFS	10	-5	-33%	$566K
61	PTE 61 DELISTED PolarityTE, Inc. Common Stock PTE	9	-3	-25%	$922K
62	62 Enlivex Ltd ENLV $4.46M	8	0	0%	$8.92M
63	63 Eterna Therapeutics ERNA $2.53M	7	0	0%	$4.47M
64	64 ARK Genomic Revolution ETF ARKG $2.09B	3	+1	+50%	$821K
65	65 DELISTED Scorpius Holdings, Inc. SCPX	2	-1	-33%	$12.3M
66	66 Qiagen QGEN $9.53B	1	0	0%	$521
67	67 Adicet Bio ACET $48.1M	–	–	–	–
68	ACHL 68 DELISTED Achilles Therapeutics ACHL	–	–	–	–
69	69 DELISTED Arcellx ACLX	–	–	–	–
70	70 Adaptive Biotechnologies ADPT $4.08B	–	–	–	–
71	AKUS 71 DELISTED Akouos Inc AKUS	–	–	–	–
72	72 Allogene Therapeutics ALLO $463M	–	–	–	–
73	73 ALPS Group Inc ALPS $56.4M	–	–	–	–
74	74 Artiva Biotherapeutics ARTV $296M	–	–	–	–
75	ATNX 75 DELISTED Athenex, Inc. Common Stock ATNX	–	–	–	–